Advertisement
AURA vs CABA
Which Stock Would AI Choose? Aura Biosciences (AURA) vs. Cabaletta Bio (CABA) Stock Comparison
Key Takeaways
- Different missions, same sector: AURA develops precision therapies for solid tumors (lead candidate bel-sar), while CABA develops engineered T-cell therapies for autoimmune diseases (lead asset rese-cel).
- Stage of pipeline: AURA is advancing a late-stage Phase 3 program in early choroidal melanoma, while CABA is earlier in clinical development across multiple autoimmune indications.
- Cash positioning: AURA completed a roughly $299 million public offering, extending its runway into the second half of 2028; CABA raised about $150 million with participation from Eli Lilly and institutional investors.
- Volatility profile: AURA has historically traded with a lower beta, while CABA exhibits materially higher volatility, reflecting differing risk profiles.
- Catalysts: AURA's next major milestone is Phase 3 (CoMpass) data expected later in 2027, while CABA is approaching pivotal myositis and additional autoimmune readouts.
- Sentiment: Both carry broadly constructive analyst coverage, though CABA's consensus skews strongly positive with a wide range of price targets.
- For more detail, explore AURA Major News and AURA Today's Price Move, as well as CABA Major News and CABA Today's Price Move.
- To see how algorithmic systems are positioned across the market, visit Trending AI Robots.
Introduction
Investors evaluating clinical-stage biotechnology names often weigh pipeline maturity, capital strength, and risk tolerance together. AURA (Aura Biosciences, Inc.) and CABA (Cabaletta Bio, Inc.) offer a useful side-by-side because both are pre-revenue developers of potentially first-in-class therapies, yet they operate in different disease areas and sit at different stages of development. This stock comparison is most relevant to growth-oriented investors and traders comfortable with binary clinical risk, as well as those comparing relative performance and market positioning among small- and mid-cap biotech companies.
AURA Overview and Recent Performance
Aura Biosciences is a clinical-stage biotechnology company focused on precision therapies for solid tumors designed to preserve organ function. Its lead candidate, bel-sar (AU-011), is in late-stage development for early choroidal melanoma, with additional early-stage work in other ocular oncology indications and bladder cancer. In recent weeks, the company underwent a leadership transition, appointing Natalie Holles as chief executive officer, and reported near-completion of enrollment in its global randomized Phase 3 CoMpass trial.
Recent market activity has been shaped by an underwritten public offering that raised roughly $299 million in gross proceeds, strengthening the balance sheet and extending the cash runway into the second half of 2028. The stock has shown a comparatively steady trend over the past year, supported by the relative maturity of its lead program. Analysts have highlighted bel-sar's strong Phase 2 tumor-control and vision-preservation data as factors underpinning sentiment, even as the long timeline to pivotal data (expected in the second half of 2027) tempers near-term catalysts.
CABA Overview and Recent Performance
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T-cell therapies, specifically chimeric antigen receptor (CAR) T-cell therapies, for B-cell-mediated autoimmune diseases. Its lead asset, rese-cel (resecabtagene autoleucel), is being evaluated across multiple indications, including myositis, systemic sclerosis, and lupus. Recent weeks have brought a series of data presentations at medical congresses, including encouraging preconditioning-free results and a 10-year commercial manufacturing agreement with Cellares.
The company also completed a $150 million underwritten offering that included participation from Eli Lilly and other institutional investors, reinforcing its balance sheet. CABA's stock has exhibited considerably higher volatility and a wider 52-week trading range than many peers, reflecting a higher-beta, higher-risk/higher-reward profile. Market sentiment has remained broadly constructive, with several analysts maintaining Buy ratings and elevated price targets, though the earlier-stage nature of its pipeline and heavier reliance on upcoming clinical readouts keep the risk profile elevated.
Trending AI Robots
Tickeron maintains hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance history, and set of securities. Because not every bot suits every market environment, only the most relevant and best-performing systems for current conditions earn a place in the curated Trending AI Robots section. This selection is designed to help traders quickly identify algorithmic strategies that align with prevailing market dynamics rather than sifting through the full catalog. If you are interested in seeing which automated approaches are currently in focus, review the Trending AI Robots page to explore the available options.
Head-to-Head Comparison
- Business model: Both are pre-revenue biotechs, but AURA targets oncology with a vision-preservation focus, while CABA targets autoimmune diseases using cell therapy.
- Growth drivers: AURA's value is tied primarily to bel-sar's Phase 3 outcome in choroidal melanoma, whereas CABA's is spread across a broader set of autoimmune indications but concentrated in a single platform asset.
- Recent momentum: AURA has shown more stable, lower-beta price behavior, while CABA has delivered stronger year-to-date gains accompanied by greater drawdowns and volatility.
- Risk factors: Both face clinical trial and regulatory risk, but CABA carries additional single-asset concentration risk and higher cash-burn sensitivity, while AURA's principal near-term risk is a long wait to pivotal data.
- Market sentiment: Analyst consensus is favorable for both, yet CABA's targets span a much wider range, signaling greater uncertainty around its valuation.
Tickeron AI Verdict
Based on observable factors such as trend consistency, volatility, pipeline maturity, and balance-sheet durability, Tickeron's AI would likely favor AURA in the current environment. AURA's later-stage lead program, extended cash runway, lower historical beta, and more stable relative performance suggest a comparatively more consistent trend profile. CABA, by contrast, presents a higher-risk/higher-reward setup with greater volatility and a wider dispersion of analyst expectations. This verdict is probabilistic rather than definitive and reflects relative positioning, not a recommendation to buy or sell either security.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AURA is a Buy and CABA is a Hold.
AURA in upward trend: 10-day moving average broke above 50-day moving average on November 10, 2026
The 10-day moving average for AURA crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on AURA as a result. In 84 of 112 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for AURA just turned positive on November 03, 2026. Looking at past instances where AURA's MACD turned positive, the stock continued to rise in 43 of 51 cases over the following month. The odds of a continued upward trend are 84%.
AURA moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +20.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where AURA advanced for three days, in 213 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 110 of 150 cases where AURA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 50-day moving average for AURA moved below the 200-day moving average on October 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AURA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
AURA broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.158) is normal, around the industry mean (3.498). P/E Ratio (-3.792) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 40 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. AURA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CABA's RSI Oscillator ascending out of oversold territory
The RSI Indicator for CABA moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In 22 of the 25 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 60 cases where CABA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for CABA just turned positive on October 22, 2026. Looking at past instances where CABA's MACD turned positive, the stock continued to rise in 43 of 49 cases over the following month. The odds of a continued upward trend are 88%.
Following a +17.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where CABA advanced for three days, in 218 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
CABA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CABA as a result. In 76 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CABA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CABA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.047) is normal, around the industry mean (3.498). P/E Ratio (-0.942) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CABA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CABA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
CABA | ||
|---|---|---|
OUTLOOK RATING 1..100 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 51 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 86 | |
P/E GROWTH RATING 1..100 | 9 | |
SEASONALITY SCORE 1..100 | 28 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| AURA | CABA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 88% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 83% |
| Momentum ODDS (%) | 2 days ago 75% | 2 days ago 84% |
| MACD ODDS (%) | 2 days ago 84% | 2 days ago 88% |
| TrendWeek ODDS (%) | 2 days ago 77% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 77% | 2 days ago 88% |
| Advances ODDS (%) | 3 days ago 77% | 3 days ago 88% |
| Declines ODDS (%) | 10 days ago 83% | 9 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 89% | 2 days ago 81% |
| Aroon ODDS (%) | 2 days ago 73% | 2 days ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AURA’s FA Score shows that 1 FA rating(s) are green while CABA’s FA Score has 1 green FA rating(s).
- AURA’s FA Score: 1 green, 4 red.
- CABA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AURA’s TA Score shows that 6 TA indicator(s) are bullish while CABA’s TA Score has 5 bullish TA indicator(s).
- AURA’s TA Score: 6 bullish, 5 bearish.
- CABA’s TA Score: 5 bullish, 3 bearish.
Price Growth
AURA (@Biotechnology) experienced а +22.60% price change this week, while CABA (@Biotechnology) price change was +2.11% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
AURA is expected to report earnings on Mar 30, 2027.
CABA is expected to report earnings on Mar 18, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
AURA and
Correlation & Price change
A.I.dvisor indicates that over the last year, AURA has been loosely correlated with CABA. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AURA jumps, then CABA could also see price increases.
| Ticker / NAME | Correlation To AURA | 1D Price Change % | ||
|---|---|---|---|---|
| AURA | 100% | -0.13% | ||
| CABA - AURA | 48% Loosely correlated | -3.33% | ||
| EDIT - AURA | 45% Loosely correlated | -8.91% | ||
| MGTX - AURA | 45% Loosely correlated | +1.37% | ||
| IDYA - AURA | 44% Loosely correlated | -0.87% | ||
| VIR - AURA | 44% Loosely correlated | -3.63% | ||
More | ||||
CABA and
Correlation & Price change
A.I.dvisor indicates that over the last year, CABA has been loosely correlated with AURA. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CABA jumps, then AURA could also see price increases.
| Ticker / NAME | Correlation To CABA | 1D Price Change % | ||
|---|---|---|---|---|
| CABA | 100% | -3.33% | ||
| AURA - CABA | 49% Loosely correlated | -0.13% | ||
| EDIT - CABA | 49% Loosely correlated | -8.91% | ||
| VIR - CABA | 47% Loosely correlated | -3.63% | ||
| NCEL - CABA | 47% Loosely correlated | +4.00% | ||
| FATE - CABA | 47% Loosely correlated | -8.76% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| APRT | 46.98 | 0.53 | +1.14% |
| AllianzIM U.S. Equity Buffer10 Apr ETF (APRT) | |||
| LQDH | 92.03 | 0.06 | +0.07% |
| iShares Interest Rate Hedged Corporate Bond ETF (LQDH) | |||
| SIMS | 45.70 | N/A | N/A |
| State Street SPDR S&P Kensho Intelligent Structures ETF (SIMS) | |||
| PSCI | 165.20 | -0.99 | -0.59% |
| Invesco S&P SmallCap Industrials ETF (PSCI) | |||
| ARKK | 77.10 | -1.88 | -2.38% |
| ARK Innovation ETF (ARKK) | |||